NR1H3 Expression is a Prognostic Factor of Overall Survival for Patients with Muscle-Invasive Bladder Cancer

Wu, Junlong; Wan, Fangning; Sheng, Haoyue; Shi, Guohai; Shen, Yijun; Lin, Guowen; Dai, Bo; Zhu, Yiping; Ye, Dingwei

doi:10.7150/jca.17845



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2017; 8(5):852-860. doi:10.7150/jca.17845 This issue Cite

Research Paper

NR1H3 Expression is a Prognostic Factor of Overall Survival for Patients with Muscle-Invasive Bladder Cancer

Junlong Wu^{1, 2*}, Fangning Wan^{1, 2*}, Haoyue Sheng^{1, 2}, Guohai Shi^{1, 2}, Yijun Shen^{1, 2}, Guowen Lin^{1, 2}, Bo Dai^1,2, Yiping Zhu^{1, 2✉}, Dingwei Ye^{1, 2✉}

1. Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China;
2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
* These authors contributed equally to this work.

Citation:

Wu J, Wan F, Sheng H, Shi G, Shen Y, Lin G, Dai B, Zhu Y, Ye D. NR1H3 Expression is a Prognostic Factor of Overall Survival for Patients with Muscle-Invasive Bladder Cancer. J Cancer 2017; 8(5):852-860. doi:10.7150/jca.17845. https://www.jcancer.org/v08p0852.htm

Other styles

Abstract

Background: Nuclear receptors (NRs) are a class of transcription factors that regulate many cellular functions through manipulation of gene expression and also play important roles in tumorigenesis, proliferation, progression and prognosis in various kinds of cancers according to recent studies. This work aimed to determine the predictive ability of NRs in muscle-invasive bladder cancer (MIBC).

Patients and methods: A total of 308 MIBC patients with complete clinicopathological and RNASeq data from The Cancer Genome Atlas (TCGA) cohort were collected for filtration. Genes showed clear correlations with overall survival (OS) and recurrence free survival (RFS) were further validated in 123 MIBC patients recruited consecutively from 2008 to 2012 in Fudan University Shanghai Cancer Center (FUSCC) cohort. Cox proportional hazards regression model and Kaplan-Meier plot were used to assess the relative factors.

Results: In TCGA cohort, we found that high NR1H3 (HR=0.779, 95% CI: 0.634 - 0.957), NR2C1 (HR=0.673, 95% CI: 0.458 - 0.989) and NR2F6 (HR=0.750, 95% CI: 0.574 - 0.980) expressions were independent factors of favorable OS, while only low NR1H3 (log-rank test, P=0.0076) and NR2F6 (log-rank test, P=0.0395) expressions had the ability to predict poor prognosis for RFS. Further, in FUSCC validating cohort, we confirmed that low NR1H3 expression level was independent factor of poor OS (HR=1.295, 95% CI: 1.064 - 1.576) and it had the ability to predict poor RFS (log-rank test, P=0.0059).

Conclusions: Low NR1H3 expression level is an independent prognostic factor of poor OS, and can also predict worse RFS in MIBC patients. Our “TCGA filtrating and local database validating” model can help reveal more prognostic biomarkers and cast a new light in understanding certain gene function in MIBC.

Keywords: Nuclear receptor, NR1H3, muscle-invasive bladder cancer, overall survival

Citation styles

APA

Wu, J., Wan, F., Sheng, H., Shi, G., Shen, Y., Lin, G., Dai, B., Zhu, Y., Ye, D. (2017). NR1H3 Expression is a Prognostic Factor of Overall Survival for Patients with Muscle-Invasive Bladder Cancer. Journal of Cancer, 8(5), 852-860. https://doi.org/10.7150/jca.17845.

ACS

Wu, J.; Wan, F.; Sheng, H.; Shi, G.; Shen, Y.; Lin, G.; Dai, B.; Zhu, Y.; Ye, D. NR1H3 Expression is a Prognostic Factor of Overall Survival for Patients with Muscle-Invasive Bladder Cancer. J. Cancer 2017, 8 (5), 852-860. DOI: 10.7150/jca.17845.

NLM

CSE

Wu J, Wan F, Sheng H, Shi G, Shen Y, Lin G, Dai B, Zhu Y, Ye D. 2017. NR1H3 Expression is a Prognostic Factor of Overall Survival for Patients with Muscle-Invasive Bladder Cancer. J Cancer. 8(5):852-860.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.